SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) is trending following its strategic $110 million acquisition of Luminar Semiconductor, a move expected to accelerate its photonic technology roadmap and expand its customer base into defense and aerospace. This development fuels community discussion, with bulls highlighting the potential of its unique room-temperature photonic chips and recent institutional investment, while skeptics point to high valuations and limited near-term revenue as major risks within the broader quantum computing sector.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Li Auto Delivers 44,246 Vehicles In December 2025

(RTTNews) - Li Auto Inc. (LI, 2015.HK) reported deliveries of 44,246 vehicles in December 2025. This performance lifted the company's fourth-quarter total to 109,194 units. By the end of the year, on...

Stock Traders Purchase Large Volume of Call Options on Li Auto (NASDAQ:LI)

Li Auto Inc. Sponsored ADR (NASDAQ:LI - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 38,208 call options on the company. This is an increase...

Top Electric Vehicle Stocks Worth Watching - December 31st

Tesla, NIO, Rivian Automotive, XPENG, Li Auto, QuantumScape, and Lucid Group are the seven Electric Vehicle stocks to watch today, according to MarketBeat's stock screener tool. Electric vehicle...

Li Auto (NASDAQ:LI) Trading Down 4.8% - Time to Sell?

Li Auto (NASDAQ:LI) Shares Down 4.8% - Time to Sell...

<ul class="summary-bullets"><li>CnEVPost reported on Wednesday, citing local media outlet LatePost, that the company is looking to reduce competition between battery electric vehicle (BEV) models and similarly priced extended-range electric vehicle (EREV) models.</li><li>The company will focus on adjusting its extended-range electric vehicle (EREV) models in the RMB 300,000 to RMB 400,000 price range, the report noted.</li><li>From January to November, Li Auto delivered 362,097 vehicles, marking a dip of over 18% &nbsp;year-on-year.</li></ul>Chinese EV maker Li Auto (LI) is reportedly preparing for a major product reshuffle as it seeks to boost sales across its pure electric vehicle and extended range electric vehicle categories. &nbsp;CnEVPost <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cnevpost.com/2025/12/31/li-auto-preparing-major-product-reshuffle/">reported</a> on Wednesday, citing local media outlet LatePost, that the company is looking to reduce competition between battery electric vehicle (BEV) models and similarly priced extended-range electric vehicle (EREV) models. Distinction between EV and EREV models priced between RMB 300,000 to RMB 400,000 will be more marked following the product realignment, the report said.Li Auto’s Li i8 pure-electric sport utility vehicle will continue to be iterated with no plans for discontinuation, the report said. The company will focus on adjusting its extended-range electric vehicle (EREV) models in the RMB 300,000 ($42,910) to RMB 400,000 price range, the report noted, while adding that it will concentrate on streamlining variant offerings.Li Auto may also introduce a premium model priced above RMB 500,000, the report said.<h2 class="st-heading-2">Li Auto’s Dwindling Sales</h2>From January to November, Li Auto delivered 362,097 vehicles, marking a dip of over 18% &nbsp;year-on-year. Through the fourth quarter (Q4), the company is looking to deliver between 100,000 and 110,000 vehicles , representing a year-over-year decrease of 37.0% to 30.7%. The company also sees a year-on-year dip in fourth quarter revenue of 40.1% to 34.2%.In comparison, Li’s rival Nio delivered 277,893 vehicles this year through November-end, marking a growth of about 46% year-over-year. XPeng, meanwhile, delivered 391,937 vehicles in the period, exceeding its annual sales target of 350,000 units.Earlier this month, HSBC downgraded Li Auto to ‘Hold’ from ‘Buy’ and slashed its price target significantly to $18.60 from $30.30. The bank cited major recalls, delivery issues, falling sales, and cut earnings estimates by 82% due to shrinking margins and an uncertain 2026 outlook.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<a href="https://stocktwits.com/symbol/LI">LI stock</a> has lost 32% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ex-walmart-ceo-bill-simon-sees-big-retail-dominating-2026-as-smaller-players-fight-to-survive/cL7B926RECR">Ex-Walmart CEO Bill Simon Sees Big Retail Dominating 2026 As Smaller Players Fight To Survive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Li Auto Inc, with the company's branding visible in the background on August 26, 2025. (Photo by Cheng Xin/Getty Images)

Li Auto Plans Major Product Reshuffle To Reverse Sales Decline: Report

The plans follow months of sales decline for the EV maker. 

Equity

(Photo credit should read INDRANIL MUKHERJEE/AFP via Getty Images)

One Chinese EV Stock Surged 80% In 2025 – But Two Others Told Very Different Stories

XPeng was the top performer in 2025, with gains of around 80%, while Li Auto’s stock declined 28% YTD.

XPeng, Nio, Li Auto Stocks Diverge Sharply In 2025: Here’s What Investors Are Watching Next

Electric Vehicle Stocks To Consider - December 30th

Tesla, Rivian Automotive, NIO, XPENG, Li Auto, Lucid Group, and QuantumScape are the seven Electric Vehicle stocks to watch today, according to MarketBeat's stock screener tool. Electric vehicle...

Nio, Li Auto, XPeng Shares Jump As Beijing Renews 2026 EV Incentives

Chinese EV makers Nio, Li Auto and XPeng are all trading higher Tuesday morning after Beijing confirmed it will roll its vehicle trade-in stimulus into 2026, easing worries about a policy cliff for...

<ul class="summary-bullets"><li>China outlined 2026 trade-in subsidies of up to 20,000 yuan for eligible new energy vehicle purchases.</li><li>Shares of Nio and XPeng climbed nearly 6%, while Li Auto edged roughly 1.3% higher.</li><li>The extension provides policy visibility as passenger vehicle sales remain weak.</li></ul>U.S.-listed shares of Chinese electric vehicle makers rose on Tuesday after China confirmed that vehicle trade-in subsidies will be extended into 2026, easing uncertainty over policy support for auto demand next year.Shares of Nio and XPeng climbed nearly 6%, while Li Auto edged roughly 1.3% higher.<h2 class="st-heading-2">Policy Extension Brings Clarity</h2>China’s National Development and Reform Commission and the Ministry of Finance said in a joint notice that trade-in subsidies for new energy vehicles will remain in place through 2026 as part of a broader consumer goods trade-in program.&nbsp;Under the policy, consumers who scrap older passenger vehicles to purchase eligible new energy vehicles could get subsidies amounting to 12% of the vehicle price, up to 20,000 yuan ($2,850).&nbsp;Those trading in vehicles, as opposed to scrapping them, can get subsidies of 8%, up to 15,000 yuan ($2,140). The incentives apply to vehicles listed in China’s catalogue qualifying for purchase tax reductions.<h2 class="st-heading-2">Taxes And Demand Backdrop</h2>The purchase tax exemption on EVs in China is in place through the end of 2025. Starting in 2026, electric vehicles will be subject to a minimum 5% purchase tax, which can be reduced by 50% through 2027 up to 15,000 yuan ($2,210) per vehicle. Automakers, such as Nio, have said they would cover the tax themselves if deliveries are pushed into the next year.The policy update comes as China’s retail passenger vehicle sales fell nearly 1% year over year in October and dropped 8.5% in November.<h2 class="st-heading-2">XPeng Seen As A Preferred Play</h2>On Monday, Morgan Stanley named XPeng among its preferred China auto stocks for the first half of 2026.&nbsp;The brokerage said the sector faces cyclical and policy challenges next year but sees these as potentially “territorially and technologically beneficial,” citing XPeng’s domestic resilience, and overseas growth. The analyst sees a chance for the stock to be valued higher if the company generates revenue or growth outside its core car-selling business.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ for Nio amid ‘high’ message volume, while XPeng and Li Auto saw ‘neutral’ sentiment, with ‘normal’ and ‘low’ message volume, respectively.One user said XPeng, Li Auto and Nio could see more than 25% upside if December 2025 sales show relative strength, adding that recent declines were driven by third quarter losses and weak fourth quarter sales guidance, which could reverse if sales outperform expectations.<stembedurl>https://stocktwits.com/BinaryLogic/message/638566326</stembedurl>Another user said Nio could achieve volume growth within China as its brands gain popularity, adding that overseas expansion is secondary and expecting the stock to surpass $30 by Dec. 30, 2026.<stembedurl>https://stocktwits.com/Dostovy/message/640408047</stembedurl>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/NIO">Nio</a> is up 29%,&nbsp;<a href="https://stocktwits.com/symbol/XPEV">XPeng</a> has climbed 84%, while&nbsp;<a href="https://stocktwits.com/symbol/LI">Li Auto</a> is down 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Nio Inc company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Nio, XPeng, Li Auto Rally After China Confirms EV Trade-In Subsidies Will Extend Into 2026

China’s 2026 trade-in incentive details lifted U.S.-listed Chinese EV stocks as investors welcomed clearer demand support.

Electric Vehicle Stocks To Research - December 28th

Tesla, Rivian Automotive, XPENG, NIO, QuantumScape, Li Auto, and Lucid Group are the seven Electric Vehicle stocks to watch today, according to MarketBeat's stock screener tool. Electric vehicle...

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.04	--	--	N/A
Q3 '25	$0.10	-$0.05	-152.24%	MISSED
Q2 '25	$0.23	$0.19	-16.28%	MISSED
Q1 '25	$0.19	$0.34	79.19%	BEAT
Q4 '24	$0.43	$0.53	21.71%	BEAT

LI
Li Auto Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest LI News

LILi Auto Inc - ADR